Immunogen (IMGN) Misses Q1 EPS Views; Revenue Light of Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Financial Fact:
Total operating expenses: 46.5M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Total operating expenses: 46.5M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.51), $0.13 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $21.12 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Natural Resource Partners (NRP) Reports Q3 EPS of $1.95
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
